An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Relay Therapeutics, a clinical-stage precision medicine company, will announce its first quarter 2024 financial results and corporate highlights on May 2, 2024. The company focuses on transforming the drug discovery process through innovative technologies.
Relay Therapeutics, un'azienda di medicina di precisione in fase clinica, annuncerà i risultati finanziari del primo trimestre del 2024 e gli aggiornamenti aziendali il 2 maggio 2024. L'azienda si concentra sulla trasformazione del processo di scoperta dei farmaci attraverso tecnologie innovative.
Relay Therapeutics, una empresa de medicina de precisión en etapa clínica, anunciará sus resultados financieros del primer trimestre de 2024 y los puntos destacados corporativos el 2 de mayo de 2024. La compañía se enfoca en transformar el proceso de descubrimiento de fármacos mediante tecnologías innovadoras.
임상 단계의 정밀 의학 회사인 릴레이 테라퓨틱스는 2024년 1분기 재무 결과와 회사 주요 소식을 2024년 5월 2일에 발표할 예정입니다. 이 회사는 혁신적인 기술을 통해 약물 발견 과정을 변혁하는 데 중점을 둡니다.
Relay Therapeutics, une entreprise de médecine de précision en phase clinique, annoncera ses résultats financiers pour le premier trimestre 2024 ainsi que les faits saillants de l'entreprise le 2 mai 2024. L'entreprise se concentre sur la transformation du processus de découverte de médicaments grâce à des technologies innovantes.
Relay Therapeutics, ein auf die Präzisionsmedizin spezialisiertes Unternehmen in der klinischen Phase, wird am 2. Mai 2024 die finanziellen Ergebnisse für das erste Quartal 2024 und Unternehmenshighlights bekannt geben. Das Unternehmen konzentriert sich darauf, den Prozess der Arzneimittelentdeckung durch innovative Technologien zu transformieren.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
